Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Lepu Biopharma Co's Enterprise Value is HK$8,487 Mil.
Lepu Biopharma Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was HK$319 Mil. Therefore, Lepu Biopharma Co's EV-to-EBIT ratio for today is 26.64.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Lepu Biopharma Co's Enterprise Value is HK$8,487 Mil.
Lepu Biopharma Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was HK$319 Mil. Therefore, Lepu Biopharma Co's EV-to-EBITDA ratio for today is 26.64.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Lepu Biopharma Co's Enterprise Value is HK$8,487 Mil.
Lepu Biopharma Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was HK$1,027 Mil. Therefore, Lepu Biopharma Co's EV-to-Revenue ratio for today is 8.26.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Lepu Biopharma Co (HKSE:02157) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Lepu Biopharma Co's current Enterprise Value is HK$8,487 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Lepu Biopharma Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was HK$319 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Lepu Biopharma Co's current Enterprise Value is HK$8,487 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Lepu Biopharma Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was HK$319 Mil.
Lepu Biopharma Co's current Enterprise Value is HK$8,487 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Lepu Biopharma Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was HK$1,027 Mil.
Lepu Biopharma Co's current Enterprise Value is HK$8,487 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Lepu Biopharma Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-14 Mil.
Lepu Biopharma Co's current Enterprise Value is HK$8,487 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Lepu Biopharma Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-145 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lepu Biopharma Co Enterprise Value Related Terms
Lepu Biopharma Co Enterprise Value Historical Data
* Premium members only.
The historical data trend for Lepu Biopharma Co's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02157 vs VRTX, REGN, RVMD: Enterprise Value Comparison
For the Biotechnology subindustry, Lepu Biopharma Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lepu Biopharma Co Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lepu Biopharma Co's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Lepu Biopharma Co's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Lepu Biopharma Co's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of HK$8,487 Mil mean?
Lepu Biopharma Co (HKSE:02157) has a Enterprise Value of HK$8,487 Mil as of Aug. 12, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Lepu Biopharma Co and its competitors.
Is Lepu Biopharma Co's Enterprise Value too high?
Lepu Biopharma Co's current Enterprise Value is HK$8,487 Mil. Overall, Lepu Biopharma Co has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lepu Biopharma Co's Enterprise Value compare to VRTX and REGN?
Lepu Biopharma Co's Enterprise Value of HK$8,487 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Lepu Biopharma Co and its competitors. Lepu Biopharma Co's current Enterprise Value is HK$8,487 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lepu Biopharma Co stock overvalued right now?
Based on GuruFocus' analysis, Lepu Biopharma Co (HKSE:02157) is currently considered Possible Value Trap. The stock's GF Value™ is HK$15.69, compared to a current price of HK$4.65 — trading 70.4% below its estimated fair value. The current Enterprise Value is HK$8,487 Mil. Lepu Biopharma Co's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Lepu Biopharma Co (HKSE:02157), the current Enterprise Value is HK$8,487 Mil as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lepu Biopharma Co (HKSE:02157) Overvalued in 2026?
Based on GuruFocus' analysis, Lepu Biopharma Co stock appears to be undervalued.
The current stock price of HK$4.65 is trading 70.4% below its estimated GF Value™ of HK$15.69.
GuruFocus considers Lepu Biopharma Co to be Possible Value Trap.
Key valuation signals for HKSE:02157:
Enterprise Value: HK$8,487 Mil
GF Value™: HK$15.69 vs. price of HK$4.65 (70.4% below fair value)
No single metric tells the full story. See the HKSE:02157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lepu Biopharma Co Ltd is focused on discovering, developing, and commercializing drug candidates in anti-tumor targeted therapy and oncology immunotherapy. Its commercial products include Puyouheng (Pucotenlimab Injection) and Meiyouheng (Becotatug Vedotin Injection). In addition, two other products, CMG901 and MRG007, have also been licensed out through its business development activities. Additionally, the company has several clinical-stage drug candidates and clinical-stage combination therapies of candidates, which are being developed as targeted therapeutics and immunotherapeutics. The various drug candidates in its pipeline include MRG003, MRG002, MRG004A, CG0070, MRG001, and MRG006A, among others. Geographically, the company generates maximum revenue from the Chinese mainland.
44GF Score
Get the complete analysis for HKSE:02157
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02157 has been successfully added to your 
